JP2018534932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534932A5 JP2018534932A5 JP2018522662A JP2018522662A JP2018534932A5 JP 2018534932 A5 JP2018534932 A5 JP 2018534932A5 JP 2018522662 A JP2018522662 A JP 2018522662A JP 2018522662 A JP2018522662 A JP 2018522662A JP 2018534932 A5 JP2018534932 A5 JP 2018534932A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- activity
- ion
- small molecule
- assay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 53
- 229920001184 polypeptide Polymers 0.000 claims 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims 52
- 150000002500 ions Chemical class 0.000 claims 20
- 150000003384 small molecules Chemical class 0.000 claims 20
- 230000000694 effects Effects 0.000 claims 19
- 238000000034 method Methods 0.000 claims 14
- 238000003556 assay Methods 0.000 claims 10
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 claims 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 229960001340 histamine Drugs 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 229910052979 sodium sulfide Inorganic materials 0.000 claims 2
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022068158A JP7390748B2 (ja) | 2015-11-02 | 2022-04-18 | 条件的活性型ポリペプチド |
| JP2023193435A JP2024020382A (ja) | 2015-11-02 | 2023-11-14 | 条件的活性型ポリペプチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562249907P | 2015-11-02 | 2015-11-02 | |
| US62/249,907 | 2015-11-02 | ||
| USPCT/US2016/019242 | 2016-02-24 | ||
| PCT/US2016/019242 WO2016138071A1 (en) | 2015-02-24 | 2016-02-24 | Conditionally active biological proteins |
| PCT/US2016/049715 WO2017078839A1 (en) | 2015-11-02 | 2016-08-31 | Conditionally active polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022068158A Division JP7390748B2 (ja) | 2015-11-02 | 2022-04-18 | 条件的活性型ポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534932A JP2018534932A (ja) | 2018-11-29 |
| JP2018534932A5 true JP2018534932A5 (cg-RX-API-DMAC7.html) | 2019-10-10 |
| JP7064769B2 JP7064769B2 (ja) | 2022-05-11 |
Family
ID=58662272
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522662A Active JP7064769B2 (ja) | 2015-11-02 | 2016-08-31 | 条件的活性型ポリペプチド |
| JP2022068158A Active JP7390748B2 (ja) | 2015-11-02 | 2022-04-18 | 条件的活性型ポリペプチド |
| JP2023193435A Pending JP2024020382A (ja) | 2015-11-02 | 2023-11-14 | 条件的活性型ポリペプチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022068158A Active JP7390748B2 (ja) | 2015-11-02 | 2022-04-18 | 条件的活性型ポリペプチド |
| JP2023193435A Pending JP2024020382A (ja) | 2015-11-02 | 2023-11-14 | 条件的活性型ポリペプチド |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11472876B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3371349A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7064769B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102714709B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN108473555B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016350613B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3003399A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2018005063A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2735023C9 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017078839A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7179400B2 (ja) * | 2014-05-13 | 2022-11-29 | バイオアトラ インコーポレイテッド | 条件的活性型生物学的タンパク質 |
| CN108473555B (zh) * | 2015-11-02 | 2022-10-25 | 生物蛋白有限公司 | 条件活性多肽 |
| US10697972B2 (en) | 2016-01-12 | 2020-06-30 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
| EP3403098B1 (en) * | 2016-01-12 | 2021-09-22 | BioAtla, Inc. | Diagnostics using conditionally active antibodies |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| KR102585956B1 (ko) * | 2016-08-31 | 2023-10-05 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 폴리펩티드 및 이를 제조하는 방법 |
| JP7244422B2 (ja) | 2017-01-11 | 2023-03-22 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｓｇｌ－１アンタゴニスト及びその使用 |
| SG10202107808SA (en) | 2017-01-18 | 2021-08-30 | F1 Oncology Inc | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
| KR20240151866A (ko) | 2017-03-14 | 2024-10-18 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
| KR102874694B1 (ko) | 2018-03-21 | 2025-10-23 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
| CA3103414A1 (en) * | 2018-06-14 | 2019-12-19 | Bioatla, Inc. | Multi-specific antibody constructs |
| CN121203021A (zh) | 2018-07-11 | 2025-12-26 | 戊瑞治疗有限公司 | 在酸性pH下结合至VISTA的抗体 |
| AU2019326407A1 (en) * | 2018-08-21 | 2021-02-18 | Bioatla, Inc. | Conditionally active proteins with pH selectivity |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| US12478674B2 (en) | 2019-04-18 | 2025-11-25 | Bristol-Myers Squibb Company | Ipilimumab variants with enhanced specificity for binding at low pH |
| WO2021257497A1 (en) * | 2020-06-15 | 2021-12-23 | Sarepta Therapeutis, Inc. | Adeno-associated virus antibodies and fragments thereof |
| US20230235054A1 (en) * | 2020-06-18 | 2023-07-27 | Bioatla, Inc. | Conditionally active anti-nectin-4 antibodies |
| IL298902A (en) * | 2020-06-18 | 2023-02-01 | Bioatla Llc | Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| EP4651894A2 (en) * | 2023-01-18 | 2025-11-26 | Harpoon Therapeutics, Inc. | Her2 targeting trispecific protein for treatment of cancer |
| IL323064A (en) * | 2023-03-02 | 2025-10-01 | Bioatla Inc | Conditionally active anti-EPCAM antibodies, antibody fragments and constructs comprising them |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| AU643109B2 (en) | 1990-12-14 | 1993-11-04 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| JPH06508985A (ja) | 1991-02-27 | 1994-10-13 | クリエイティブ バイオモレキュルズ インコーポレイテッド | 富セリンペプチドリンカー |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| GB9320668D0 (en) | 1993-10-07 | 1993-11-24 | Secr Defence | Liposomes containing particulare materials |
| GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
| HUT76369A (en) | 1994-07-29 | 1997-08-28 | Smithkline Beecham Corp | Novel soluble protein compounds |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| ATE331438T1 (de) | 1995-01-17 | 2006-07-15 | Brigham & Womens Hospital | Rezeptorspezifischer transepithelealer transport von immunogenen |
| US6168804B1 (en) | 1995-06-07 | 2001-01-02 | University Of Alberta | Method for eliciting Th1-specific immune response |
| US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| DE69925461T2 (de) | 1998-02-09 | 2006-04-27 | Bracco International B.V. | Zielgerichtete abgabe von biologische-aktive medien |
| DE69909459T2 (de) | 1998-04-21 | 2004-05-27 | Micromet Ag | Cd19xcd3 spezifische polypeptide und deren verwendung |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| US20020028178A1 (en) | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| AU6461201A (en) | 2000-07-12 | 2002-01-21 | Idec Pharma Corp | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| MXPA03002262A (es) | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
| CA2443694A1 (en) | 2001-04-09 | 2002-10-17 | Progenics Pharmaceuticals, Inc. | Anti-cd19 immunotoxins |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| DK1381402T3 (da) | 2001-04-27 | 2010-03-08 | Vivoxid Oy | Fremgangsmåde til forbedring af blødvævsmodtagelse og implantater der gør brug af denne fremgangsmåde |
| DE10248103A1 (de) | 2001-10-17 | 2003-05-15 | Schneider Gmbh & Co Kg | Verfahren zum Herstellen einer Linse, insbesondere einer Brillenlinse |
| US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| EP1511861A4 (en) * | 2002-06-12 | 2007-12-05 | Genencor Int | METHODS AND BINDING COMPOSITIONS DEPENDENT FROM THE MEDIUM OF A TARGET AGENT TO A TARGET |
| US20040064050A1 (en) | 2002-09-20 | 2004-04-01 | Jun Liu | System and method for screening tissue |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US20050260711A1 (en) * | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
| WO2006031370A2 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2009021232A2 (en) | 2007-08-09 | 2009-02-12 | Massachusetts Institute Of Technology | High-throughput, whole-animal screening system |
| JP2010068746A (ja) * | 2008-09-18 | 2010-04-02 | Chiba Univ | 抗腫瘍効果を有する化合物の同定方法 |
| BRPI1006141B8 (pt) | 2009-01-12 | 2021-05-25 | Cytomx Therapeutics Llc | composições de anticorpo modificado, métodos para preparar e usar as mesmas |
| DK2406399T3 (en) | 2009-03-09 | 2018-03-12 | Bioatla Llc | MIRAC PROTEINS |
| DK3042957T3 (en) | 2009-07-17 | 2018-01-02 | Bioatla Llc | At the same time, integrated selection and development of human protein performance and expression in production hosts |
| US20110143960A1 (en) | 2009-12-10 | 2011-06-16 | Labarbera Daniel V | 3d-models for high-throughput screening drug discovery and development |
| US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
| JP6121904B2 (ja) * | 2010-09-08 | 2017-04-26 | ハロザイム インコーポレイテッド | 条件的活性治療用タンパク質を評価および同定する、または発展させる方法 |
| WO2013040445A1 (en) | 2011-09-15 | 2013-03-21 | Whitehead Institute For Biomedical Research | Arrays for cell-based screening and uses thereof |
| EP3778889A1 (en) | 2011-09-30 | 2021-02-17 | Chugai Seiyaku Kabushiki Kaisha | Ion concentration-dependent binding molecule library |
| BR112014022228A2 (pt) * | 2012-03-08 | 2017-07-11 | Halozyme Inc | anticorpos anti-epidérmicos de receptor de fator de crescimento condicionalmente ativo e métodos de uso dos mesmos |
| US20140206596A1 (en) * | 2013-01-18 | 2014-07-24 | University Of Southern California | Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions |
| JP7179400B2 (ja) | 2014-05-13 | 2022-11-29 | バイオアトラ インコーポレイテッド | 条件的活性型生物学的タンパク質 |
| CN108473555B (zh) * | 2015-11-02 | 2022-10-25 | 生物蛋白有限公司 | 条件活性多肽 |
| KR102585956B1 (ko) * | 2016-08-31 | 2023-10-05 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 폴리펩티드 및 이를 제조하는 방법 |
-
2016
- 2016-08-31 CN CN201680077540.7A patent/CN108473555B/zh active Active
- 2016-08-31 CA CA3003399A patent/CA3003399A1/en active Pending
- 2016-08-31 EP EP16862643.0A patent/EP3371349A1/en active Pending
- 2016-08-31 RU RU2018115781A patent/RU2735023C9/ru active
- 2016-08-31 KR KR1020187014104A patent/KR102714709B1/ko active Active
- 2016-08-31 KR KR1020247032903A patent/KR20240150525A/ko active Pending
- 2016-08-31 MX MX2018005063A patent/MX2018005063A/es unknown
- 2016-08-31 AU AU2016350613A patent/AU2016350613B2/en active Active
- 2016-08-31 WO PCT/US2016/049715 patent/WO2017078839A1/en not_active Ceased
- 2016-08-31 JP JP2018522662A patent/JP7064769B2/ja active Active
- 2016-08-31 US US15/773,122 patent/US11472876B2/en active Active
- 2016-08-31 CN CN202211275600.XA patent/CN115521374B/zh active Active
-
2018
- 2018-04-24 MX MX2023001319A patent/MX2023001319A/es unknown
-
2022
- 2022-04-18 JP JP2022068158A patent/JP7390748B2/ja active Active
- 2022-08-19 US US17/820,913 patent/US20220403024A1/en active Pending
-
2023
- 2023-11-14 JP JP2023193435A patent/JP2024020382A/ja active Pending
- 2023-12-21 AU AU2023285915A patent/AU2023285915A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534932A5 (cg-RX-API-DMAC7.html) | ||
| RU2018115781A (ru) | Условно активные полипептиды | |
| JP2020536488A5 (cg-RX-API-DMAC7.html) | ||
| HRP20251020T1 (hr) | Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3 | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| JP2018521638A5 (cg-RX-API-DMAC7.html) | ||
| JP2014518883A5 (cg-RX-API-DMAC7.html) | ||
| JP2016196468A5 (cg-RX-API-DMAC7.html) | ||
| JP2019529350A5 (cg-RX-API-DMAC7.html) | ||
| RU2012131671A (ru) | Способ полипептидной модификации для очистки полипептидных мультимеров | |
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| Lu et al. | Frontier of therapeutic antibody discovery: The challenges and how to face them | |
| JP2025063133A (ja) | 原発性免疫不全症、シスチン症、及びウィルソン病に関する新生児スクリーニング | |
| WO2024086617A3 (en) | Ph-dependent anti-cd3 antibodies and methods relating thereto | |
| KR20230017778A (ko) | 골수성 세포 염증성 표현형을 조절하기 위한 항-vsig4 조성물 및 방법, 그리고 이의 용도 | |
| WO2021112676A3 (en) | Methods and means for attracting immune effector cells to tumor cells | |
| WO2020225799A3 (en) | A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein | |
| US20250084178A1 (en) | Anti-cd39 antibodies and use thereof | |
| EP3103810A3 (en) | Modified variable domain molecules and methods for producing and using them | |
| AR095499A1 (es) | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b | |
| PE20240224A1 (es) | Anticuerpo biespecifico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8 | |
| JP2018537117A5 (cg-RX-API-DMAC7.html) | ||
| JP6665274B2 (ja) | 標的分子に結合するポリペプチドの決定方法及び決定システム | |
| WO2019066620A3 (ko) | 항 c-met 항체 및 이의 용도 |